Trial Profile
A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study Evaluating The Efficacy And Safety Of Tanezumab For The Treatment Of Moderate To Severe Pain Associated With Interstitial Cystitis/ Painful Bladder Syndrome (IC/PBS)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Tanezumab (Primary)
- Indications Interstitial cystitis; Pain
- Focus Therapeutic Use
- 26 Mar 2022 This trial has been completed in Belgium and Finland (Global end date: 21 Jan 2021), according to European Clinical Trials Database record..
- 19 May 2015 Pooled analysis (1035, 1010, 1019) results presented at the 110th Annual Meeting of the American Urological Association.
- 21 Mar 2012 This trial is recruiting in Belgium, Spain and suspended in Finland.